Early life nutritional supplements and later metabolic disease. by Prentice, Andrew M
Prentice, AM (2018) Early life nutritional supplements and later
metabolic disease. The Lancet Global health, 6 (8). e816-e817. ISSN
2214-109X DOI: https://doi.org/10.1016/S2214-109X(18)30308-5
Downloaded from: http://researchonline.lshtm.ac.uk/4648600/
DOI: 10.1016/S2214-109X(18)30308-5
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: http://creativecommons.org/licenses/by/2.5/
Comment
www.thelancet.com/lancetgh   Vol 6   August 2018 e816
Early life nutritional supplements and later metabolic disease
The theory of the Developmental Origins of Health 
and Disease is supported by many association studies 
showing that people who had a nutritionally adverse 
start in life, assessed with proxies of low birthweight 
or slow postnatal growth, have an increased risk for 
a range of metabolic diseases.1 The depth of evidence 
is substantial, but the breadth and diversity is poor. 
Numerous prospective studies have been done in 
short-lived small animals, usually with a low-protein 
diet as the model for nutritional adversity; such 
experiments tend to support data from observational 
studies in humans.2 A key feature of these studies is 
that metabolic vulnerability, which is programmed 
during crucial windows of development, is exposed by 
later weight gain and obesity.3 Metabolic adaptation 
to a poor nutrient supply in early life is hypothesised 
to create an adaptive state of the thrifty phenotype4 
that becomes maladaptive when a later obesogenic 
diet and lifestyle change the nutritional circumstances. 
These circumstances commonly occur in low-
income countries as they progress through economic 
transition.5
In the August issue of The Lancet Global Health, 
Ford and colleagues6 add an important new piece 
to the puzzle by reporting the later-life metabolic 
and health outcomes of an early-life protein-energy 
supplementation trial done in Guatemala in 1969–77. 
Unfortunately, the results show beneficial and 
detrimental outcomes that create as many questions as 
answers, and do not clearly inform future public health 
interventions.
The Institute of Nutrition of Central America and 
Panama developed a protein-energy supplement 
(Atole) and a protein-free control supplement (Fresco), 
which were offered to pregnant women and young 
children in four villages; two matched villages each. The 
investigators followed up 1139 (69%) of 1661 traceable 
participants from an original cohort of 2392 children 
enrolled in 1969–77. This high level of attrition raises 
the possibility of loss-to-follow-up bias; however, with 
the exception of sex (ie, more men migrated out of the 
study area than women), the authors provide adequate 
assurance that such bias is unlikely. Nonetheless, the 
analysis is based on only 139 women and 86 men who 
received Atole and were available for follow-up.
A second statistical challenge is the inherent weakness 
of cluster randomisation to two versus two villages; 
essentially, randomisation to Atole versus Fresco is 
the same as randomisation to villages 1 and 2 versus 3 
and 4. Therefore, chance differences could exist between 
the villages, especially over such long periods of follow-
up. In a best effort to overcome this limitation, the 
authors used a difference-of-differences approach in 
which, in addition to studying the differences between 
supplements (villages), they also compared the 
outcomes for children within each village who were 
enrolled before the study versus those enrolled during 
the study.
Participants receiving Atole from conception to age 
2 years had a significantly higher body-mass index 
(1·29 kg/m², 95% CI 0·08–2·50), body fat (1·73%, 
0·20–3·26), and odds ratio for obesity (1·94, 1·11–3·40) 
and central obesity (2·53, 1·18–5·43). Participants 
also had a more atherogenic lipid profile (total 
cholesterol and non-HDL cholesterol) that remained 
significant after adjusting for the probable mediators 
of body-mass index and waist-to-height ratio. A 
tendency towards increased diastolic blood pressure 
was reported, which was initially significant in men, 
but not after adjustment for body composition. By 
contrast, exposure to Atole offered strong protection 
against diabetes defined as raised fasting or 2-h post-
challenge glucose or use of diabetes medication, or 
both (OR 0·46, 95% CI 0·21–0·97).
Follow-up of the Institute of Nutrition of Central 
America and Panama study has shown that Atole 
improved child survival, improved growth, and 
enhanced human capital assessed by educational 
attainment and income; these benefits can be added 
to the apparent protection against diabetes. However, 
despite these benefits, the adverse atherogenic findings 
forced the authors to a final unsatisfactory conclusion 
that nutritional supplementation programmes should 
consider the potential mixed consequences for adult 
cardiometabolic health.
Where do we go from here? A first step would be 
to avoid the use of epidemiological simplifications 
when trying to interpret physiological or metabolic 
outcomes and define crucial windows of exposure. 
The authors repeatedly state that supplementation 
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was from conception to age 2 years and refer to the 
first 1000 days.6 The first 1000 days is an advocacy 
tool and confuses interpretation, particularly because 
the parental methylation marks inherited from ovum 
and sperm are erased and re-established in the first 
10 days after conception, and emerging research 
shows that these essential processes are sensitive to 
parents’ nutrient status, which depends on their diet 
before conception.7 Atole supplementation started in 
early pregnancy and not, as stated, at conception, thus 
missing these early programming events.
Second, additional metabolic studies can enhance 
understanding of epidemiology and thus help address 
factors that might explain the surprising mismatch 
between the diabetic and atherogenic findings. This 
recommendation touches on an outstanding challenge 
in the field of cardiometabolic disease—namely, what 
mechanisms exist linking excess adiposity to adverse 
metabolic outcomes? The role of inflammation,8 
including gut-derived inflammation,9 might be 
key in low-income settings and could be studied 
prospectively in this valuable cohort.
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